ALLO Allogene Therapeutics Inc

Price (delayed)

$24.51

Market cap

$3.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.83

Enterprise value

$3.3B

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by ...

Highlights
The EPS has grown by 14% YoY
ALLO's quick ratio is down by 41% year-on-year
Allogene Therapeutics's equity has decreased by 12% YoY and by 4.3% QoQ

Key stats

What are the main financial stats of ALLO
Market
Shares outstanding
142.18M
Market cap
$3.48B
Enterprise value
$3.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.39
Price to sales (P/S)
86.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
86.04
Earnings
Revenue
$38.39M
EBIT
-$238.72M
EBITDA
-$231.18M
Free cash flow
-$193.08M
Per share
EPS
-$1.83
Free cash flow per share
-$1.43
Book value per share
$7.23
Revenue per share
$0.28
TBVPS
$8.36
Balance sheet
Total assets
$1.13B
Total liabilities
$102.91M
Debt
$51.21M
Equity
$1.02B
Working capital
$556.17M
Liquidity
Debt to equity
0.05
Current ratio
13.09
Quick ratio
12.98
Net debt/EBITDA
0.79
Margins
EBITDA margin
-602.2%
Gross margin
100%
Net margin
-621.8%
Operating margin
-629.4%
Efficiency
Return on assets
-20.1%
Return on equity
-22.2%
Return on invested capital
-25%
Return on capital employed
-22.1%
Return on sales
-621.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLO stock price

How has the Allogene Therapeutics stock price performed over time
Intraday
-1.96%
1 week
-2.93%
1 month
15.89%
1 year
-32.5%
YTD
-2.89%
QTD
-6.02%

Financial performance

How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$38.39M
Gross profit
$38.39M
Operating income
-$241.63M
Net income
-$238.72M
Gross margin
100%
Net margin
-621.8%
The net income has decreased by 5% YoY and by 4.4% QoQ
Allogene Therapeutics's net margin has decreased by 4.2% from the previous quarter
ALLO's operating income is down by 3.4% since the previous quarter
The operating margin has declined by 3.2% since the previous quarter

Growth

What is Allogene Therapeutics's growth rate over time

Valuation

What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
3.39
P/S
86.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
86.04
The EPS has grown by 14% YoY
ALLO's price to book (P/B) is 17% less than its last 4 quarters average of 4.1
Allogene Therapeutics's equity has decreased by 12% YoY and by 4.3% QoQ

Efficiency

How efficient is Allogene Therapeutics business performance
ALLO's return on invested capital is up by 32% year-on-year but it is down by 5% since the previous quarter
The return on equity has increased by 26% year-on-year but it has declined by 8% since the previous quarter
The return on assets has increased by 26% year-on-year but it has declined by 7% since the previous quarter
The ROS has contracted by 4.2% from the previous quarter

Dividends

What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLO.

Financial health

How did Allogene Therapeutics financials performed over time
ALLO's quick ratio is down by 41% year-on-year
ALLO's current ratio is down by 41% YoY
Allogene Therapeutics's debt is 95% less than its equity
Allogene Therapeutics's equity has decreased by 12% YoY and by 4.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.